The aim of the present analysis was to estimate the cost-effectiveness of intense insulin treatment after acute myocardial infarction in patients with diabetes mellitus based on the results of the Diabetes Mellitus Insulin Glucose Infusion in Acute Myocardial Infarction (DIGAMI) study. In this study 620 patients with diabetes mellitus and acute myocardial infarction were randomized to intense insulin treatment (insulin group) or to serve as controls given standard antidiabetic therapy. Mortality was significantly reduced in the insulin group.
Introduction
Diabetes mellitus is an important risk factor for cardiovascular disease. Mortality after a myocardial infarction is considerably higher for patients with diabetes mellitus than for patients without diabetes mellitus, both in the acute phase and during long-term follow-up [1] [2] [3] [4] . Thus it is important to develop more effective treatment strategies, particularly since diabetic patients account for up to 20% of the total number of individuals admitted to coronary care units for suspect myocardial infarction [1] . The DIGAMI (Diabetes Mellitus Insulin Glucose Infusion in Acute Myocardial Infarction) study tested whether improved metabolic care by means of intense insulin therapy could improve survival. In all, 620 diabetic patients were randomly assigned to intense insulin treatment (insulin group) or served as controls (control groups). The intensive insulin treatment consisted of an insulin-glucose infusion for at least 24 h followed by subcutaneous multidose insulin for at least 3 months. One year mortality was significantly reduced from 26% to 19% [5] . During long-term follow-up (mean 3·4 years; range 1·6-5·6 years) the mortality difference increased further, see Fig. 1 . The overall mortality was 33% in the infusion group compared to 44% in the control group [6] . Thus, the DIGAMI study demonstrated that intense insulin treatment after myocardial infarction improves survival among patients with diabetes mellitus. Before a treatment strategy is recommended for substantial patient populations it is important to verify that it is cost-effective, i.e. provides good value for money compared to other health improving measures [7, 8] . The aim of this analysis is to estimate the cost-effectiveness of intense insulin treatment after acute myocardial infarction in patients with diabetes mellitus based on the results of the DIGAMI study.
Methods
The cost-effectiveness was estimated as the incremental cost per life-year gained and quality-adjusted lifeyear gained of intense insulin treatment compared to standard therapy without intense insulin treatment as derived from the DIGAMI control group [7, 8] . The analysis was carried out from a societal perspective including health care costs as well as indirect costs (decreased labour production) [8] . These costs were estimated in detail for the first year of follow-up. Since no data were available as regards resource consumption for subsequent years it was assumed that the cost per patient year was the same for both groups thereafter. It has recently been argued that the difference between total consumption and total production during an increase in length of life should be added to the costs in cost-effectiveness analysis [9] [10] [11] . We therefore included these future costs. According to current practice [12] both costs and effectiveness were discounted at 3%. All costs were estimated in 1999 Swedish Crowns, but the results are presented in 1999 prices in Euro, based on the exchange rate in June 1999 (Euro 1=SEK 8·70).
Costs for antidiabetic therapy
The cost of therapy for the diabetic condition was divided into the cost for the insulin-glucose infusion in the insulin group and the cost for oral antidiabetics and subcutaneous insulin in both groups. Use of oral therapy and subcutaneous insulin was recorded for each patient in the trial as a basis for calculating the treatment costs. The official Swedish retail prices for insulin were used [13] . Since no detailed data were available as regards insulin consumption after the first year of follow-up, it was assumed that the cost of insulin did not differ between the two groups during the remaining period of follow-up.
Costs for the initial hospitalization
The costs for the initial hospitalization were divided into costs for hospital days, costs for thrombolytic therapy and costs for pacemakers. Data on the quantities of these resources were collected in the trial. The cost of thrombolysis was based on the official Swedish retail price of streptokinase, and a cost of Euro 115 was used [13] . The cost per hospital day of Euro 521 and the cost of a pacemaker of Euro 4116 was based on cost estimations at the participating centres in the DIGAMI study.
Health care costs from discharge to 12 months
The number of hospital days, the number of PTCA and CABG procedures, and the number of outpatient physician visits were recorded in the trial from discharge to 12 months of follow-up. The unit costs for these resources were based on cost estimations at the participating centres in the DIGAMI study. The following unit costs were used: Euro 211 per hospital day, Euro 5207 per PTCA, Euro 10 090 per CABG, and Euro 157 per outpatient physician visit.
Labour productivity during the first year of follow-up
The working status of each patient was recorded at the 3 and 12 month follow-up visits. The working status was estimated as the percentage of full time work for each patient. The labour production was estimated for the period from discharge until 3 months and the period from 3 months to 12 months. The average working status during the first of these periods was assumed to be an average of the working status at discharge (assumed to be 0 for all patients) and 3 months. The average working status during the second period was assumed to be an average of the working status at 3 and 12 months. To estimate the labour production the working status was multiplied by the average value of labour production of a Swedish worker (Euro 29 655 per year) [14] .
Future costs during the increased length of life
How to deal with costs that arise due to an increase in the length of life (i.e. costs during the added years) is one of the oldest controversies in this field [7] [8] [9] [10] [11] [12] . The solution to the controversy about costs in added years is that the difference between total consumption and total production in added years should be included as a cost in cost-effectiveness analysis [8] [9] [10] [11] . We therefore include these full future costs of added years in the analysis.
The total consumption can be divided into the nonhealth care consumption and the health care consumption. As annual non-health care consumption we used the average in Sweden for the population above 65 years of age (Euro 14 253) [10] . For the annual health care consumption we used the average health care costs in the intense insulin group and the control group during the first year excluding the costs of the initial hospitalization and the cost of the insulin-glucose infusion. This was divided by the survival time during the first year to yield an annual health care consumption of Euro 5862. The total annual consumption per added year was thus assumed to be Euro 20 115.
To estimate the annual production in added years we used the average working status of the insulin and control group patients alive at the 12 months visit (14% of full working capacity). Multiplying this by the annual production of a full time worker yielded an annual production of Euro 4138. Accordingly we used an annual consumption minus production of Euro 15 977 (20 115-4138) as the future cost per added year.
Life-years gained
The number of life-years gained was defined as the increase in life-expectancy as a result of intense insulin treatment compared to the treatment in the control group. Data on long-term survival in the trial population has been reported in detail elsewhere [5, 6] . In brief the patients were followed-up up to 5·6 years (mean 3·4 years). The actuarial mortality curves in the two groups from randomization to 5 years of follow-up are shown in Fig. 1 . The life-years gained during years 0-5 were estimated as the area between the survival curves.
To estimate the total number of life-years gained it is also necessary to know the survival after the 5th year. In the base-case analysis we assumed a constant annual morality risk of 20% for the survivors at 5 years. This yields a life-expectancy of 5 years for a person alive at 5 years [15] [16] . Furthermore it was conservatively assumed that the annual mortality risk after the 5th year would be equal for patients in the insulin and the control groups. We also varied the mortality risk after the fifth year in a sensitivity analysis (see below).
Quality-adjustment of life-years gained
To overcome the disadvantage of using only life-years gained as the effectiveness measure, paying no attention to the health status during the gained life-expectancy, quality-adjusted life-years gained were also used as an effectiveness measure. Quality-adjusted life-years were constructed by weighting years of life with a weight between 0 (dead) and 1 (full health) corresponding to the health status in the year. Since no specific information on quality of life was collected in the DIGAMI trial, it was assumed that quality of life did not differ between the two treatment groups. A recent study estimated the average quality weight in the Swedish general population to be about 0·80 in the 60-79 age-group [17] . According to other studies a myocardial infarction reduces the quality weight by about 0·10 [18] [19] . A quality weight of 0·70 (0·80-0·10) was therefore used in the present study to adjust life-years for quality of life. Since the 0·70 quality weight is an approximation it was varied in a sensitivity analysis (see below).
Sensitivity analysis
Very few studies have included the full future costs of added life-years and for comparability the costeffectiveness was therefore estimated without these costs. Since some studies only include health care costs we estimated the cost-effectiveness with only such costs included. This estimation was performed both with and without health care costs of added years of life. One estimation was included in which the labour production after the first year of follow-up was assumed to be zero (due to the high mean age of this patient population). This increases the annual consumption minus production in added years from Euro 15 977 to Euro 20 115.
From Figure 1 it is evident that the number of patients at risk during long-term follow-up decreases over time, increasing the uncertainty of the survival curves. Cost-effectiveness was therefore calculated with a similar annual mortality in both groups after 3 or 4 rather than 5 years. Another uncertain variable is the annual mortality after 5 years of follow-up. This was varied between 10% and 100% in a sensitivity analysis. The quality of life weight was varied between 0·8 and 0·6 and finally, we varied the discount rate for both cost and effectiveness between 0% and 5%, and in one analysis costs were discounted at 3% but effectiveness not at all.
Statistical analysis
Differences between the groups in quantity of resources consumed and costs during the first year of follow-up were tested for significance. For continuous variables mean values were compared by two-tailed independent samples t-test [20] . The independent samples t-test is robust for non-normality if the hypothesis of equal
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variances cannot be rejected [20] . The variance only differed significantly between samples for one variable (the cost of oral antidiabetics) and in that case the non-parametric Mann-Whitney test was used for comparisons. For discrete variables a contingency table chi-square test was used [20] . A P-value below 0·05 was considered statistically significant.
Results

Health care consumption during the first year of follow-up
The use of medical resources during the initial hospitalization and from hospital discharge to 12 months is reported in Table 1 . Although not statistically significant the number of hospital days during the initial hospitalization was 1·4 more in the infusion than in the control group (P=0·098). The number of outpatient visits was higher in the infusion group (P=0·005). It should be noted that the proportion of patients undergoing PTCA and CABG was rather low in both treatment groups. As long as the number of PTCA and CABG does not differ between the treatment groups a higher proportion of patients undergoing PTCA and CABG would, however, not affect the cost difference between the groups. The health care costs during the first year of follow-up is presented in Table 2 . The overall cost of insulin was Euro 60 higher in the infusion group (P<0·001). The overall costs during the initial hospitalization were Euro 798 higher in the infusion group (P=0·068). Apart from 
Labour production during the first year of follow-up
There was no significant differences in labour production between the two groups ( Table 3 ). The total labour production during the first year of follow-up was Euro 2383 in the infusion group and Euro 2358 in the control group, i.e. a difference of Euro 25 (P=0·961).
Life-years gained
The estimated life-expectancy measured from randomization was 6·41 years in the infusion group and 5·26 years in the control group, i.e. a difference of 1·15 years. Of this increase in life-expectancy 0·43 years was the difference in the survival curves for years 0-5 in Fig. 1 , and the rest was due to more patients being alive in the infusion group at the end of 5 years. If life-years were discounted at 3% the gain in life-years decreased to 0·94. If this gain in life-years was adjusted for quality of life, the gain decreased further to 0·66 quality-adjusted life-years.
Cost-effectiveness
The net incremental cost per patient in the infusion group was estimated as the increased health care costs of Euro 975 during the first year of follow-up (from Table 2 ), minus the increased labour production of Euro 25 (from 
Sensitivity analysis
The result of the sensitivity analysis is shown in Table 4 . If the future costs of increased life-expectancy were excluded the cost-effectiveness ratio would decrease substantially to Euro 1000 per life-year gained and Euro 1500 per quality-adjusted life-year gained. If only health care costs were included (including health care costs in added years) the cost per life-year gained would be Euro 6600 and the cost per quality-adjusted life-year gained Euro 9400. If only the health care costs in the first year of follow-up were included the results would be similar to the example without future costs. If the estimation of future costs was based on the labour production being none after the first year of follow-up the costeffectiveness ratio would increase slightly compared to the baseline estimate.
If it was assumed that the mortality rate was the same for both groups after 3 or 4 years of follow-up rather than 5 years, the estimated gain in discounted life-years would be decrease from 0·94 years to 0·68 years and 0·69 years. This, however, would have little effect on the cost-effectiveness ratio. Since the major part of the net cost is the future cost of added life-years this cost would decrease when the gain in life-years decreased. For the same reason the variation in the annual mortality risk after the 5 years of follow-up had little effect on the cost-effectiveness ratio, although it caused a variation in the discounted gain in life-years between 0·40 years (100% annual mortality risk after five years) and 1·35 years (10% annual mortality risk after 5 years).
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Varying the discount rate between 0% and 5% had little effect on the result. This is because the discounting reduced both the gain in life-years and the future costs of added life-years. If the effectiveness was not discounted at all while costs were discounted by 3% the cost per life-year gained would decrease to Euro 13 800 and the cost per quality-adjusted life-year gained decreased to Euro 19 800.
Discussion
Previous reports from the DIGAMI study revealed that intense insulin treatment improves survival during longterm follow-up [5] [6] . It can be estimated that lifeexpectancy will increase by 1·15 years in the infusion group (0·94 years with 3% discounting). Since the gained life-years cannot be expected to be in full health they were adjusted for quality of life. The estimated gain in quality-adjusted life-years was 0·80 (0·66 with 3% discounting). An increased life-expectancy will be associated with a cost for society that equals the difference between total consumption and total production during the added years of life. It has recently been advocated that such future costs should be included in costeffectiveness analysis [9] . A failure to include these costs will, for instance, discriminate against programmes that improve quality of life of elderly patients [9] [10] [11] . We therefore included future costs in the analysis. Adding the future costs to the costs of the first year of follow-up (Euro 950) led to an incremental cost per patient in the infusion group of Euro 15 882. To enable comparisons with previous studies that have not included future costs we also estimated the cost-effectiveness ratios without future costs.
The incremental cost was divided by the discounted increase in life-expectancy and quality-adjusted lifeexpectancy, which yielded a cost per life-year gained of Euro 16 900 and a cost per quality-adjusted life-year gained of Euro 24 100. To be able to interpret whether the estimated cost-effectiveness ratios are high or low we need to know how much society is willing to pay to gain a life year or quality-adjusted life-year. The only sector in Sweden where this 'price' has been explicitly stated is in cost-benefit analyses of road investments, where a price of Euro 1·5 million per life saved is used [21] . The Euro 1·5 million per life saved used in economic evaluations of road investments implies a price of about Euro 80 000 per life-year gained and about Euro 90 000 per quality-adjusted life-year gained (at a 3% discount rate). To make these figures useful as a benchmark for the health care field they should be adjusted for differences in the treatment of taxes in economic evaluations of road investments and health care in Sweden. With these adjustments the price decreases to about Euro 50 000 per life-year gained and about Euro 60 000 per qualityadjusted-life-year gained. Using the same value of increased survival as in road investments in Sweden, intense insulin treatment is highly cost-effective, since the estimated cost-effectiveness ratios are far below this benchmark. It is also common to compare the costeffectiveness ratios of alternative uses of health care resources to implicitly decide what society is willing to pay per life-year or quality-adjusted life-year gained. In most studies, treatments with cost-effectiveness ratios below Euro 20 000 are considered to be highly costeffective, while those above Euro 100 000 are considered not to be cost-effective [22] [23] [24] [25] [26] [27] [28] . Although the cost per quality-adjusted life-year gained is slightly above the Euro 20 000 benchmark it is well below the Euro 100 000, suggesting that the treatment is costeffective.
A problem in comparing the cost effectiveness ratio in this study with other studies is that most other studies did not include the full future costs. If the future costs are not included the cost per life-year gained decreases to Euro 1000 and the cost per quality-adjusted life-year gained decreases to Euro 1500. The only Swedish study that has included the full future costs is a costeffectiveness analysis of treatment of mild hypertension [10] . In that study the cost per quality-adjusted life-year gained was of the same magnitude as in DIGAMI for middle-aged and older men and women with mild hypertension. For younger men and women with mild hypertension the cost per quality-adjusted life-year gained was considerably higher than in DIGAMI. It was considered that the treatment was cost-effective among middle-aged and older men and women with mild hypertension [10] . Accordingly it may be concluded that the results of the economic analysis of the DIGAMI study indicates that intense insulin treatment after acute myocardial infarction in patients with diabetes mellitus is cost-effective.
